**Request to Share Care and Agreement Form**

**Use of oral lanthanum for hyperphosphataemia in adult patients in adult patients with**

**chronic kidney disease: shared care protocol: guideline No 14; version 2.2**

This request to share care provides key primary care information on responsibilities and monitoring. The aim is to support the GP to agree to share care arrangements. Refer to full shared care protocol for further information.

**GP to review and must respond to provider Trust request to share care within 2 weeks**. **This form is used to agree shared care between the specialist, patient and GP and a copy of the form to be retained in 1.Patients’ hospital records, 2. Given to patient, and 3. Retained in GP notes.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Patient Information or Addressograph label** | | **Drug information** | |
| Patient name: |  | Drug(s) and Dose at handover: |  |
| DOB: |  | Indication: |  |
| NHS number: |  | Estimated date for prescribing to be continued by the GP: |  |
| Patient weight (kg): |  | Date of first prescription by specialist |  |
| Next monitoring tests due and dates: | |  | |
| Specialist additional comments/advice: | |  | |

|  |  |  |
| --- | --- | --- |
| **Specialist and patient agreement**  **By signing below we accept:**   * The Herts and West Essex Area Prescribing Committee [shared care principles](https://www.hweclinicalguidance.nhs.uk/all-clinical-areas-documents/download?cid=1739&checksum=752d25a1f8dbfb2d656bac3094bfb81c) (HWE APC) and * The requirements and responsibilities defined in this drug specific shared care protocol | | |
| Specialist name: | Specialist signature: | |
| Designation: | Date: | |
| Direct telephone: | Patient signature or specialist confirmation of patient agreement to shared care arrangement: | |
| Provider trust: |
| Email/ Shared care email for use by GP: | Date: | |
| **GP response to shared care**  **Please return to specialist within two weeks of receipt of request to share care.**  ***This form is to be completed by the GP who is requested to share care.***  I agree to accept shared care for this patient as set out in this shared care protocol and APC [shared care](https://www.hweclinicalguidance.nhs.uk/all-clinical-areas-documents/download?cid=1739&checksum=752d25a1f8dbfb2d656bac3094bfb81c) principles  I do not accept shared care for this patient  My reason(s) for not prescribing are given below (refer to GP considerations for shared care at end of protocol): | | |
| GP name: | | Practice Address/Stamp: |
| Direct telephone number: | |
| Email: | |
| Date: | | GP Signature: |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Key Primary Care Information (refer to Full Shared Care Protocol for further information)**  **GP RESPONSIBILITIES**   * Consider request to shared care arrangements and prompt completion and emailed return of signed response to the Specialist using the Shared Care Agreement Form within 14 days of its receipt. * If shared care accepted prescribe lanthanum once the patient is clinically stable. This is usually within 8-12weeks after initiation of therapy. * Prescribe as per recommendation from specialist. Ensure ongoing monitoring undertaken by specialist. * There should be reciprocal sharing of blood tests between the GP and specialist. * Re-iterating with the patient that non-attendance for blood testing may lead to withdrawal of the medication. Further help and advice can be sought from the hospital specialist team. * Appropriately prompt notification to the hospital Specialist of any significant and relevant changes in the patient’s condition or of an adverse reaction, referring to Specialist should any serious side effects occur. Stop treatment on advice of the Specialist or immediately if an urgent need to stop treatment arises such as bowel obstruction. * Ensure no drug interactions with other medicines. * Change dose or stop treatment as advised by Specialist. * Report adverse events to the Specialist and MHRA/CHM.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | **MONITORING AND ACTIONS TO BE TAKEN**  **Monitoring Table – see GP monitoring highlighted in grey.**   |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | | **Monitoring table** | | **Hospital specialist** | **Hospital specialist** | **Hospital specialist** | **GP** | **Hospital specialist** | | **Test** | **Indication** | Pre-treatment baseline | During TreatmentInitiation | Following Treatment  Initiation | Ongoing | Annual review | | Serum phosphorus | Baseline and ongoing assessment for disease and drug dose assessment | √ | Monthly | \*Monthly –  2 to 3 monthly | Not required by GP | √ | | Serum calcium | √ | Monthly | \*Monthly –  2 to 3 monthly | Not required by GP | √ | | Parathyroid hormone | √ | 3 monthly | 3 monthly | Not required by GP | √ | | \*Dialysis patients are monitored routinely monthly, non-dialysis patients are routinely monitored every 2-3months (see also page 4) | | | | | | | | **Action to be taken if Abnormal Result**  GP will be informed by specialist via letter.  (Normal reference range may vary slightly between labs. Results should be recorded in the patient’s shared care monitoring record booklet (where in use). Please note an unusual fall or rise or a consistent downward or upward trend in any value should prompt review of the patient and extra vigilance. Some patients may have abnormal baseline values, Specialist will advise) | | | | | | | | |

* The expectation is that this information along with the full protocol provides sufficient information to enable GPs to be confident to take on the clinical & legal responsibility for prescribing.
* Prescribing and monitoring responsibility will only be transferred under this shared care protocol when:
* Specialist has initiated treatment and prescribed/monitored treatment for initial stabilisation period.
* Specialist has provided pre-treatment counselling and discussed patient responsibilities, preferences and obtained consent to shared care arrangements.
* Specialist and patient have completed and signed the shared care agreement form (page 1).

**Full Shared Care Protocol**

**Use of oral lanthanum for hyperphosphataemia in adult patients in adult patients with**

**chronic kidney disease: shared care protocol: guideline No 14; version 2.2**

**This full protocol provides prescribing and monitoring guidance. It should be read in conjunction with HSW APC shared care principles,** [**Summary of Product Characteristics (SPC)**](https://www.medicines.org.uk/emc) **and the** [**BNF**](http://www.bnf.org/bnf/index.htm)**.**

**BACKGROUND AND INDICATION(S) FOR USE**

Disturbance of mineral metabolism is a common complication associated with chronic kidney disease (CKD). As renal function declines parathyroid hormone levels start to rise, this is driven by a fall in calcitriol production, hypocalcaemia and hyperphosphataemia.

The management of hyperphosphataemia is crucial and is one of the most important factors in the development of secondary hyperparathyroidism (SHPT). SHPT contributes significantly to the high incidence of morbidity and mortality seen in people with CKD. The management of hyperphosphataemia involves dietary restriction of phosphate, the use of oral phosphate binders and adequate dialysis (CKD stage 5). Available data and opinion suggests that dietary phosphate restriction should be initiated when parathyroid hormone levels start to rise, and/or when serum phosphate levels are elevated. As dietary restriction alone is unlikely to control serum phosphate levels in CKD stage 4 and 5, phosphate binders will be required.

Phosphate binders are indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease. A number of phosphate binders are available which may be used in the context of a multiple therapeutic approach, and these include calcium carbonate (Calcichew®), calcium acetate (Renacet®), sevelamer hydrochloride (Renagel®), sevelamer carbonate (Renvela®),sucroferric oxyhydroxide(Velphoro®) and **lanthanum (Fosrenol****®).** These products may be used in combination with 1α-hydroxycholecalciferol (alfacalcidol) or one of its analogues, or cinacalcet to control the development of renal bone disease.

NICE guideline NG203 (August 2021) recommends:

- the use of the calcium-based phosphate binder calcium acetate as the initial binder therapy for patients with chronic kidney disease, in conjunction with dietary phosphorous restriction, to control phosphorus and parathyroid levels. (Consider patient preference and use calcium carbonate if calcium acetate not suitable).

- offer sevelamer carbonate if calcium acetate is not indicated (for example, because of hypercalcaemia or low serum parathyroid hormone levels) or not tolerated. If hypercalcaemia develops with the use of calcium-based binders, it may be necessary to convert to a non-calcium containing phosphate binder, or to use a combination of both.

- If calcium acetate and sevelamer carbonate cannot be used, consider using sucroferric oxyhydroxide for patients on dialysis.

- Consider lanthanum only if other phosphate binders cannot be used.

- Consider patient preference utilising other formulations such as oral powders where available when the patient is unable to swallow tablets.

Kidney Disease Improving Global Outcomes (KDIGO) guidelines suggest lowering elevated phosphate levels towards the normal range and avoiding hypercalcaemia.

\*For patients on haemodialysis corrected calcium and phosphate are monitored monthly. For non-haemodialysis patients, corrected calcium and phosphate are monitored at each clinic visit and more frequently if there are concerns.

**DOSAGE, ROUTE OF ADMINISTRATION AND DURATION OF TREATMENT**

**Adult dosage and administration**

**Preparations available:** Lanthanum 500mg chewable tablets, lanthanum 750mg chewable tablets, lanthanum 1000mg chewable tablets, lanthanum 750mg oral powder sachets and lanthanum 1000mg oral powder sachets.

Control of serum phosphate level has been demonstrated at doses starting from 750 mg per day. The maximum dose studied in clinical trials, in a limited number of patients, is 3,750 mg. Patients who respond to lanthanum therapy usually achieve acceptable serum phosphate levels at doses of 1,500 to 3,000 mg lanthanum per day.

Serum phosphate levels should be monitored and the dose of lanthanum titrated every two to three weeks until an acceptable serum phosphate level is reached, with regular monitoring thereafter.

Lanthanum should be taken with or immediately after food, with the daily dose divided between phosphate-containing meals. Patients should adhere to recommended diets in order to control phosphate and fluid intake. Tablets must be chewed and not swallowed whole.

Swallowing difficulties

Please refer to the [‘specials’ alternative guidance](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.hweclinicalguidance.nhs.uk%2Fall-clinical-areas-documents%2Fdownload%3Fcid%3D2274%26checksum%3D95f8d9901ca8878e291552f001f67692&data=05%7C02%7Cheernamehta%40nhs.net%7Ccba67ac584344a90298108dcafcc3bcd%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638578538908037976%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=drWPIVzT4RkMn0VJJa96%2F2dIm19xPNtqcc0yghL%2FsEA%3D&reserved=0) for a list of commonly prescribed medicines and alternative methods of administration for patients with swallowing difficulties, feeding tubes or for patients prescribed unlicensed ‘specials’ medication. Each entry takes into account alternative medicines, formulations, cost and licensing. This list is not exhaustive. As not all medicines are listed, please contact the initiating specialist if required for individual patient advice if a patient has a swallowing difficulty.

|  |
| --- |
| **SPECIALIST RESPONSIBILITIES INCLUDING PRE-TREATMENT ASSESSMENT**   * Diagnose and assess if patient is suitable for treatment with lanthanum and initiate treatment. * Undertake pre-treatment counselling and document discussion in patient’s records. Provide patient/carer with relevant (preferably written) information on use, side effects, need for monitoring of medication and precautions including that no new medicines are started (including over the counter preparations) unless this has been discussed with the GP, specialist or pharmacist. * Obtain agreement and consent to share care. Complete and sign Specialist and patient agreement section of Shared Care Agreement form. Document in patient’s notes and transfer once patient stabilised. * Request for GP confirmation of acceptance of shared care by secure emailing of request to share care, protocol and completed agreement form, allowing 2 weeks for response. * Receipt and recording in patient records/notes that GP has / has not accepted shared care and ensuring appropriate action if not (specialist to continue to prescribe/monitor). * Prescribe for initial stabilisation period. This is usually 8-12 weeks. * Undertake baseline and ongoing tests as indicated in the monitoring table. Review results of safety monitoring and request additional tests as required. * Continue to review the patient at agreed specified intervals, sending a written summary to the GP whenever the patient is reviewed. * Monitor response and adverse effects to treatment and need to continue therapy. Notify the GP of any changes to dose or cessation of therapy. * Advise the GP on when to adjust the dose or to stop treatment. * Notify GP if patient does not attend clinic repeatedly and advise on action to take. * Specify formulation prescribed in correspondence. * Provide any other advice, information or support for the GP if required. Communicate any clinically important issues and action to be taken and ensure clear back-up arrangements exist for GPs to obtain advice and support. * Report any adverse events to MHRA/CHM and the GP. * Support any training arrangements to ensure that GPs have the skills to ensure safe practice. |

**GP RESPONSIBILITIES**

Refer to page 2 and GP Considerations for Shared Care page 7.

|  |
| --- |
| **PATIENT RESPONSIBILITIES IN COOPERATION WITH SPECIALIST AND GP**   * Confirm their agreement with the decision to move to a shared care model for their ongoing care and their understanding of the shared care agreement. * Consent to share care and complete/sign Specialist and patient agreement section of Shared Care Agreement form. * Take the lanthanum as prescribed. * Attending for blood monitoring and follow up hospital or GP appointments. *(Cont. page 6)* * Report to the Specialist or GP if they subsequently do not have a clear understanding of the treatment. * Ensuring a list of all medications is brought to all GP surgery, outpatient and A&E consultations. * Reporting any change in symptoms and adverse effects promptly to the clinician who is currently prescribing. * Confirm that no new medicines are started (including over the counter preparations) unless this has been discussed with the GP, specialist or pharmacist. * Share any concerns in relation to treatment with lanthanum with the Specialist or GP. * Inform Specialist, or GP, of any other medication being taken, including over-the-counter products. * Alert GP/specialist of any changes of circumstance which could affect management of disease e.g. plans for pregnancy, plans to move/change GP practice |

|  |
| --- |
| **DISPENSING PHARMACIST RESPONSIBILITIES**   * Confirming that the patient has received verbal and written patient counselling / information and provide additional counselling should this be required. · Check the patient is being monitored regularly to ensure that it is safe before issuing or dispensing prescriptions. * Confirming that the patient has received verbal and written patient counselling / information and provide additional counselling should this be required. |

|  |
| --- |
| **MONITORING AND ACTIONS TO BE TAKEN**   * Refer to page 2. |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **SIDE EFFECTS AND ACTIONS TO BE TAKEN (REFER TO** [**BNF**](http://www.bnf.org/bnf/index.htm) **AND** [**SPC**](http://www.medicines.org.uk/emc) **for full details)**   * GP to liaise with specialist if any side effects are a cause for concern.  |  |  | | --- | --- | | **SIDE EFFECTS** | **Action to be taken by GP** | | Gastro- intestinal effects e.g. nausea, vomiting, diarrhoea, stomach pain, heartburn, flatulence, constipation | **Common - Monitor and inform specialist if symptoms become significant** | | Gastroenteritis, laryngitis, ileus, intestinal obstruction, irritable bowel syndrome, oesophagitis, stomatitis, indigestion, dry mouth, tooth disorder, eructation | Uncommon - inform specialist | | Alopecia, increased sweating | Uncommon - If mild, reassure and continue.  If significant, contact specialist team to discuss treatment alternatives. | | Hyperparathroidism, hypercalcaemia, hyperglycaemia, hyperphosphataemia, hypophosphataemia, anorexia, increased appetite | Uncommon - inform specialist.  Specialist will monitor calcium phosphate and parathyroid levels and advice. | | Vertigo | Uncommon - inform specialist | | Taste alteration and dizziness | Uncommon - inform specialist | |

**CONTRAINDICATIONS AND PRECAUTIONS**  **(REFER TO** [**BNF**](http://www.bnf.org/bnf/index.htm) **AND** [**SPC**](http://www.medicines.org.uk/emc) **for full details)**

**Hypophosphataemia:** Lanthanum should be avoided in patients with low phosphate levels.

Exercise caution in all patients predisposed to gastrointestinal obstruction, ileus, sub-ileus and gastro-intestinal perforation

Lanthanum is **not recommended in pregnancy**. Lanthanum should only be used in **breast-feeding women after taking into account the potential benefit of breast feeding to the child and the potential benefit of lanthanum therapy to the nursing mother.**

**NOTABLE DRUG INTERACTIONS (REFER TO** [**BNF**](http://www.bnf.org/bnf/index.htm) **AND** [**SPC**](http://www.medicines.org.uk/emc) **for full details)**

**Common drug interactions:**

Lanthanum carbonate hydrate may increase gastric pH therefore all compounds which are known to interact with antacids should not be taken within 2 hours of lanthanum (e.g. chloroquine, hydroxychloroquine and ketoconazole).

**Levothyroxine:** reduced absorption of levothyroxine- give at least 2 hours apart and closer monitoring of TSH levels is recommended in patients receiving both medicinal products.

**Tetracyclines and doxycycline**: theoretically interacts if both compounds are co-administered- recommended to give 2 hours apart

**Ciprofloxacin:** oral bioavailability of ciprofloxacin is reduced by approximately 50%. Oral floxacin formulations should be taken at least 2 hours before or 4 hours after lanthanum

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **CONTACT DETAILS for BACK-UP INFORMATION / ADVICE**  **East and North Hertfordshire NHS Trust**   |  |  |  |  |  | | --- | --- | --- | --- | --- | | **Department** | **Contact number** | **Specialist Team designated nhs.net email** | **Pharmacy Team shared care admin contact** | **Out of hours contact / switchboard** | | **Consultant Nephrologists** | Via switchboard | nephadmin.enh-tr@nhs.net | [sharedcare.enh-tr@nhs.net](mailto:sharedcare.enh-tr@nhs.net)  01438 284032 | 01438 314333 | | **Clare Morlidge/ Charlotte Mallindine**  Renal pharmacists | 01438 284677 | renalpharmacists.enh-tr@nhs.net | | **Gail Franklin**  **Renal dieticians** | 01438 284947 | renaldieticians.enh-tr@nhs.net |   **Outside normal working hours there is access to a Consultant Nephrologist via the hospital switchboard**  **Communication**  For any queries relating to a patient’s treatment with lanthanum, please contact the Specialist as documented at the top of this document. Read in conjunction with HWE APC shared care principles document.  For advice if you have any concerns contact the specialist team. If unable to contact specialist team or out of hours, contact medical registrar on call. |

**REFERENCES**

* Shire Pharmaceuticals Ltd. Fosrenol 500 mg, 750 mg and 1,000 mg tablets Summary of Product Characteristics 2019 *www.medicines.org.uk*
* *Chronic Kidney Disease: assessment and management; . assessment and management; NICE guideline 203* [*https://www.nice.org.uk/guidance/ng203*](https://www.nice.org.uk/guidance/ng203) *(accessed October 2023*
* KDIGO 2017. *Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).* Official journal of the international society of nephrology Volume 7 Issue 1: July 2017

**GP Considerations for Shared Care**

This shared care agreement outlines suggested management for the prescribing of the specified drug(s) and indication(s) when the responsibility is shared between the specialist and general practitioner (GP). Sharing of care assumes communication between the specialist, GP and patient. It is important that patients are consulted about treatment and are in agreement with it. The intention to share care should be explained to the patient by the doctor initiating treatment and consent obtained.

Prescribing is to be initiated in secondary care by a provider Trust specialist and will usually be prescribed for 12 weeks unless otherwise stated within the agreed individual shared care protocol**. The expectation is that these shared care guidelines should provide sufficient information to enable GPs to be confident to take on the clinical and legal responsibility for the prescribing and the monitoring of this / these drug(s) in stable patients.** The questions below will help you confirm this:

* Is the patient’s condition predictable or stable?
* Do you have the relevant knowledge, skills and access to equipment to allow you to monitor treatment as indicated in this shared care document?
* Have you been provided with relevant clinical details including monitoring data?
* Have this document and BNF/SPC provided sufficient information for you to feel confident in accepting clinical and legal responsibility for prescribing?

**If you can answer YES to all of these questions (after reading this shared care guideline), then it is appropriate for you to accept the prescribing responsibility. GPs need to formally accept shared care by completing and returning the form provided within this protocol to the specialist within two weeks of receipt of request to share care.**

If the answer is NO to any of these questions, you should not accept prescribing responsibility. You should respond back to the consultant outlining your reasons for NOT prescribing on the agreement form within two weeks of receiving the request to share care. If you do not have the confidence to prescribe, you still have the right to decline. In such an event, the total clinical responsibility for prescribing the medication and any monitoring required remains with the specialist. Please note that medication cost is not an acceptable reason for refusal to take on shared care.

The prescribing doctor legally assumes clinical responsibility for the drug and the consequences of its useas well as responsibility of monitoring (securing and reviewing blood test results).

Prescribing and monitoring responsibility will only be transferred when the consultant and the GP agree that the patient’s condition is stable or predictable. This will usually be 12 weeks of treatment unless otherwise stated within the agreed individual shared care protocol.

**Approval Information**

|  |  |
| --- | --- |
| Title of Guideline | Use of oral lanthanum for hyperphosphataemia in adult patients in adult patients with  chronic kidney disease: shared care protocol |
| Guideline Number | 1 |
| Version | 2.2 Updated in line with new shared care protocol template May 2025  2.1 Updated with wording on swallowing difficulties and patient consent to shared care. September 2024 |
| Review Date | This shared care guidance will be reviewed upon request in the light of new evidence becoming available |
| Original Version Produced | 2 |
| ***Approvals:*** |  |
| Provider Trust Drug / Formulary Management Group | To be noted at East and North Hertfordshire NHS Trust Therapeutics Policy Committee |
| Hertfordshire and West Essex area prescribing committee | November 2023 |
| Author/s | East and North Hertfordshire NHS Trust Pharmacy department and relevant specialisms supported by HWE ICB Pharmacy and Medicines Optimisation Team |
| Department(s) responsible for updating the guideline | East and North Hertfordshire NHS Trust Pharmacy department and relevant specialisms supported by HWE ICB Pharmacy and Medicines Optimisation Team |